The leadership in the House has been working on its legislation to reform lobbying disclosure and ethics practices and is expected to unveil the plan today, May 15, or tomorrow, May 16, with a mark-up of the bill in the Judiciary Committee expected May 17. Despite repeated statements that a bill will be filed soon, controversy over grassroots lobbying disclosure, limits on bundling of campaign contributions by registered lobbyists and expansion of the cooling off period before ex-members of Congress can lobby have stalled progress. Rumors abound that the Democratic leadership bill will address the revolving door issue by doubling the cooling off period to two years. But the other two issues — grassroots lobbying disclosure and bundling of campaign contributions — are not likely to be addressed, although the leadership seems willing to have them offered as amendments or separate bills.

The U.S. Environmental Protection Agency (EPA) announced a final rule on May 10 to increase reporting of dioxin compounds, some of the most potent carcinogens, under the Toxics Release Inventory (TRI) program.

On May 9, the Senate ended weeks of debate and passed S. 1082, the Food and Drug Administration Revitalization Act. The two primary aims of the bill are to renew the Prescription Drug User Fee Act and to generally strengthen the regulatory authority of the U.S. Food and Drug Administration (FDA).